Form 4: Pliant Therapeutics Director Acquires 26,764 Shares Via Option Grant

Director John T. Curnutte acquired 26,764 shares of Pliant Therapeutics through an option grant on June 13, 2024.

Summary

• On June 13, 2024, John T. Curnutte, a director of Pliant Therapeutics, Inc. acquired 26,764 shares of common stock through an option grant.
• The exercise price of the option is $13.06.
• The options vest quarterly, with 25% vesting on the first day of each calendar quarter for three quarters following the grant date.
• The remaining 25% vests on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of shares through an option grant, which can be seen as a slightly positive signal but doesn't provide strong evidence for a bullish or bearish outlook.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Key Dates